Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials
在ER阳性、HER2阴性晚期乳腺癌中，伊姆鲁司群联合阿贝西利与氟维司群联合阿贝西利的疗效比较：三项III期试验的间接治疗比较
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2026.106091
Jhaveri, K; Bidard, F C; Kalinsky, K; Neven, P; Rugo, H S; Tolaney, S M; Litchfield, L M; von Laue, C C; Traore, S; Sapunar, F; Li, Y; O'Shaughnessy, J
